Hong Kong stocks surge | Quanxin Biological-B (02509.HK) rose more than 8% in early trading QX027N obtains two clinical trial implied permits planned for the treatment of asthma and atopic dermatitis

According to the Wise Finance and Economics APP, Sinobioway Biomedicine-B (02509.HK) surged more than 8% in the morning session. As of the time of writing, it had risen by 8.45% to HK$22.08, with a trading volume of 5.603 million Hong Kong dollars.